Navigation Links
Micromet Highlights Clinical Plans and Regulatory Strategy for Lead Product Candidate Blinatumomab at its Annual R&D Day
Date:2/10/2010

s in the EU and US, the Company plans to design and conduct an exploratory Phase 2 single-arm study in adult patients with relapsed/refractory CLL. The Company currently plans to initiate patient enrollment by the end of 2010.

Webcast replay

A replay of the Company's R&D Day webcast, along with presentation slides, is available through a link on Micromet's web site at www.micromet-inc.com.  

About Blinatumomab

Blinatumomab (MT103) is a novel, next-generation monoclonal antibody designed to direct the body's cell destroying T-cells against CD19, a protein expressed on the surface of most B-cell derived non Hodgkin's lymphomas. Blinatumomab has demonstrated potent activity against adult Acute Lymphocytic Leukemia, achieving an 80% molecular response rate in a Phase 2 study. Blinatumomab was generally well-tolerated by patients in the Phase 2 study.  The most frequently reported grade 3/4 adverse event was lymphopenia.  All other adverse events were infrequent and transient in nature.  Micromet received orphan drug designation from the EMEA for blinatumomab for the treatment of ALL in August 2009.

About Acute Lymphocytic Leukemia

Acute Lymphocytic Leukemia (ALL) is a cancer of the blood and bone marrow that afflicts 5,760 patients in the U.S. annually.(1)  ALL is the most common type of cancer in children. The average five-year survival rate for adult ALL patients after 1st relapse is 7%.  The presence of minimal residual disease, or MRD, is a recognized negative prognostic factor for patients with ALL.  According to published results(2), MRD-negative patients incurred a 6% ri
'/>"/>

SOURCE Micromet, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Final Data from Phase 2 Study Confirm High Response Rate of Micromets Blinatumomab in Patients with Acute Lymphoblastic Leukemia
2. Bayer Schering Exercises Option to Develop Solid Tumor BiTE Antibody with Micromet
3. Micromet to Present at The 8th Annual BIO Investor Forum Conference on October 29, 2009
4. Micromets Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients
5. Micromet Presents Update on Blinatumomabs Response Rate and Duration in a Phase 1 Study in Non-Hodgkins Lymphoma Patients
6. Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day
7. Micromet Presents Preclinical Data Showing Activity of Erbitux and Vectibix Based BiTE Antibodies against KRAS- and BRAF-mutated Human Colorectal Cancer Cells
8. Micromet Receives Milestone Payment for Filing of the First Clinical Trial Application for MT203
9. Micromet Has Started a New Phase 2 Trial with Adecatumumab in Colorectal Cancer Patients
10. Micromet Key Events for 2009
11. Micromet Expands Committed Equity Financing Facility to $75 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... Calif. , July 22, 2014  Based ... imaging (MRI) market, Frost & Sullivan recognizes Siemens ... Product Leadership. Siemens Healthcare,s FREEZEit solution, which employs ... need for robust and motion-insensitive imaging. The solution,s ... the evolution of body MRI imaging in the ...
(Date:7/22/2014)... TUCSON, Ariz. , July 22, 2014 /PRNewswire/ ... recipient of a SynCardia temporary Total ... of Rochester,s Strong Memorial Hospital with the Freedom® ... heart. Fontana, a 64-year-old retiree from ... disease—cardiomyopathy—for decades. He managed the condition with medications, ...
(Date:7/22/2014)... , July 22, 2014  PuraMed BioScience®, ... of over-the-counter (OTC) medicinal and healthcare products, announced ... of Operation Troop Aid. "We are ... Russell Mitchell , CEO and Chairman of PuraMed ... women in combat zones experience migraines much more ...
Breaking Medicine Technology:Frost & Sullivan Recognizes Siemens Healthcare with the Product Leadership Award for Innovative Techniques in Abdominal Imaging 2Frost & Sullivan Recognizes Siemens Healthcare with the Product Leadership Award for Innovative Techniques in Abdominal Imaging 3Frost & Sullivan Recognizes Siemens Healthcare with the Product Leadership Award for Innovative Techniques in Abdominal Imaging 4'I'm a Heartless SOB' Jokes Patient Discharged from Strong Memorial Hospital without a Human Heart 2'I'm a Heartless SOB' Jokes Patient Discharged from Strong Memorial Hospital without a Human Heart 3PuraMed BioScience Partners with Operation Troop Aid to Sponsor Care Packages 2PuraMed BioScience Partners with Operation Troop Aid to Sponsor Care Packages 3
... leading biopharmaceutical company dedicated to the research and development ... disorders, is marking Digestive Disease Week (DDW) 2012 in ... lives of patients with Crohn,s disease. UCB will present ... "DDW is an exciting opportunity for UCB to ...
... 17, 2012  Eisai announced today that 15 abstracts highlighting new ... Annual Meeting of the American Society of Clinical Oncology (ASCO), ... 2012. These studies highlight Eisai,s current product ... and their families affected by cancer. "Our ...
Cached Medicine Technology:UCB Proudly Reinforces Long-Standing Commitment to Crohn's Disease Community at Digestive Disease Week 2012 2UCB Proudly Reinforces Long-Standing Commitment to Crohn's Disease Community at Digestive Disease Week 2012 3UCB Proudly Reinforces Long-Standing Commitment to Crohn's Disease Community at Digestive Disease Week 2012 4Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting 2Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting 3Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting 4Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting 5Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting 6Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting 7Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting 8Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting 9
(Date:7/22/2014)... American Society of Hematology (ASH) will honor Michael DeBaun, ... Robert P. Hebbel, MD, of the University of Minnesota ... Prize for their significant research advances in the area ... named for the late Ernest Beutler, MD, a past ... years, is a two-part lectureship that recognizes major translational ...
(Date:7/22/2014)... director of research at the University of Utah,s John ... International Society of Eye Research (ISER) as the recipient ... Kayser International Award in Retina Research., The award recognizes ... a significant contribution to the understanding of vitreoretinal diseases ... at the ISER Biennial Meeting in San Francisco, where ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 Legislation ... Seniors Access to Local Pharmacies Act of 2014”) ... Part D would undermine the availability of lower ... by $21 billion over the next 10 years, ... released by the Pharmaceutical Care Management Association (PCMA). ...
(Date:7/22/2014)... WASHINGTON -- Autoimmune disorders may share certain pathogenic mechanisms ... Washington University (GW) researcher Linda Kusner, Ph.D. , ... , This paradigm shifting work shows that the very ... are also expressed in cells that produce autoimmune diseases. ... of Neurology at the GW School of Medicine and ...
(Date:7/22/2014)... The Beryl Institute announces its fifth annual Patient ... These offerings reinforce the Institute’s commitment to support the ... the need for rigorous research to understand and address ... are intended to encourage and support research into ... the patient experience before, during and after care (e.g., ...
Breaking Medicine News(10 mins):Health News:Michael DeBaun, M.D., M.P.H., and Robert P. Hebbel, M.D., to present 2014 ASH Beutler Lecture 2Health News:Michael DeBaun, M.D., M.P.H., and Robert P. Hebbel, M.D., to present 2014 ASH Beutler Lecture 3Health News:Michael DeBaun, M.D., M.P.H., and Robert P. Hebbel, M.D., to present 2014 ASH Beutler Lecture 4Health News:University of Utah researcher Robert Marc receives Paul Kayser International Award 2Health News:PCMA: New Study Finds H.R. 4577 to Cost $21 Billion Over 10 Years 2Health News:New research finds pathogenic connection between autoimmune disorders and cancer 2Health News:The Beryl Institute Opens Applications for 2014 Patient Experience Grant and Scholar Programs 2Health News:The Beryl Institute Opens Applications for 2014 Patient Experience Grant and Scholar Programs 3
... fluid in the middle ear, a condition called otitis media ... by antihistamines and decongestants, a new review of studies has ... in alleviating symptoms or avoiding complications of OME and expose ... ,"This review finds no benefit for any of the ...
... Virginia University professor and two alumni have tracked the ... the eye and often leads to blindness and death.// ... treatment for those who suffer from it. ,Joginder ... doctoral students Jason White ('02) and Alison Director-Myska ('96) ...
... Federal government of Australia came under the glaring critics ... its allocation of funds for various health promotion programs.// ... at the current government for lapses pertaining to health ... from rural medical facilities pharmaceuticals and after hour care ...
... the gut has been found to be an effective ... researchers at Cedars-Sinai Medical Center. ,The study ... the Annals of Internal Medicine It is the ... end of the course of treatment has ended. This ...
... reports that the board of the Central Gippsland Health Service ... ,Peter Goss and Jo McCubbin had resigned from the Sale ... such an action because of threats to services. However they ... place. ,In an open letter to the hospital board, ...
... Cancer’s exploits are titillated by personality traits, contemplates a ... rodents//. The idea that personality types may increase the ... ,Researchers at the University of Chicago ... point for cancer as compared to the rats that ...
Cached Medicine News:Health News:Allergy Drugs More Harmful Than Helpful for Chronic Ear Inflammation 2Health News:Allergy Drugs More Harmful Than Helpful for Chronic Ear Inflammation 3Health News:Team Tracks Genetic Origins of Eye Cancer 2Health News:Federal government blamed for allocating meager portion to health sector:ALP 2Health News:IBS Sufferers Benefited by Non-Absorbable Antibiotics 2
... The BacT/Alert 3D Signature is ... microbial detection system that integrates blood, ... It is a powerful microbiology workstation ... for higher volume identification and where ...
... Vitek is a completely automated instrument that ... 2 - 6 hour same day turnaround), ... control module. It is used for bacterial ... urine screening and has a complete data ...
IDS Rapid One, a microbial identification system....
The Cogent Microbial Luminescence System (MLS) is a superior Rapid microbial detection system for UHT product screening combining proven technology of ATP-bioluminescence with unsurpassed hardware in...
Medicine Products: